Top 10 CROs of 2024

In the fast-paced world of clinical trials, staying on top of the latest trends is crucial for success. As you start up your studies in 2024, it's important to keep in mind the Contract Research Organizations (CROs) that will shape the industry in the coming year. CROs play a vital role in optimizing clinical trials for success and have the potential to make or break a study. Let's take a look at the top 10 CROs to watch for in 2024.

‍

1. QuintilesIMS (IQVIA): As a global leader in healthcare intelligence, QuintilesIMS (now part of IQVIA) is expected to continue playing a pivotal role in shaping the CRO landscape. With a comprehensive range of services, they are likely to maintain their position as a key player in 2024.
2. Lindus Health: Lindus Health aims to run clinical trials three-times faster than the traditional CRO. With a robust background in digital therapeutics and diagnostics and an emerging presence in pharma, this organization is expected to become a key player in the industry.
3. Covance (LabCorp): Covance's integrated approach to drug development, leveraging their parent company LabCorp's resources, positions them as a CRO to watch. Their commitment to end-to-end solutions and innovation is likely to make them a significant player in the coming years.
4. PPD: Known for its focus on efficiency and global reach, PPD is expected to be a prominent CRO in 2024. Their diverse portfolio of services and dedication to accelerating clinical trials make them an ideal candidate for many therapeutic areas.
5. ICON plc: With a strong emphasis on adaptive trial designs and data-driven strategies, ICON plc is likely to maintain its position as a top CRO to watch. Their broad spectrum of services and global presence adds to their significance in the industry.
6. Syneos Health: The integrated capabilities of Syneos Health, combining clinical and commercial expertise, make them a standout CRO. As pharmaceutical companies seek more comprehensive solutions, Syneos Health is expected to be a key player in 2024.
7. Catalent: Specializing in advanced delivery technologies, development solutions, and integrated clinical supply services, Catalent is anticipated to be a CRO to watch. Their focus on providing end-to-end solutions may contribute to their growing influence.
8. Medpace: With a reputation for high-quality and efficient clinical development services, Medpace is likely to be on the radar in 2024. Their therapeutic expertise and commitment to customer satisfaction make them a notable CRO.
9. Charles River Laboratories: As a leading provider of preclinical and clinical services, Charles River Laboratories is expected to be a CRO of significance. Their focus on early-phase research and comprehensive offerings in drug discovery contribute to their standing.
10. Celerion: Specializing in early-phase clinical research, Celerion is poised to be a CRO to watch in 2024. Their expertise in conducting efficient and cost-effective Phase I studies adds to their appeal.

‍

Conclusion

In conclusion, there are a wide range of CROs to help take on your clinical trials in 2024. As we dive into 2024, the U.S. CRO landscape is teeming with promise and innovation. IQVIA, Covance, PPD, ICON plc, and Medpace are just a handful of the CROs expected to spearhead groundbreaking research initiatives, supporting the nation's pharmaceutical and biotech industries.

At Lindus Health, we provide a comprehensive suite of services to ensure your study's success from start to finish. Our all-in-one eClinical platform and end-to-end service offering are designed to streamline your clinical trials, keeping you at the forefront of innovation. Book a meeting with our team today and take the first step towards optimizing your conversion rates and driving growth with Lindus Health.